ID: ALA254618

Max Phase: Preclinical

Molecular Formula: C17H16Cl2N6O

Molecular Weight: 391.26

Molecule Type: Small molecule

Representations

Canonical SMILES:  COCCCn1cnc2c(NCc3ccc(Cl)c(Cl)c3)nc(C#N)nc21

Standard InChI:  InChI=1S/C17H16Cl2N6O/c1-26-6-2-5-25-10-22-15-16(23-14(8-20)24-17(15)25)21-9-11-3-4-12(18)13(19)7-11/h3-4,7,10H,2,5-6,9H2,1H3,(H,21,23,24)

Standard InChI Key:  ZPWRCRYJTMZRFV-UHFFFAOYSA-N

Molecule Features

Natural Product: No

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type: Small molecule

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Properties

Molecular Weight: 391.26

Molecular Weight (Monoisotopic): 390.0763

AlogP: 3.65

#Rotatable Bonds: 7

Polar Surface Area: 88.65

Molecular Species: NEUTRAL

HBA: 7

HBD: 1

#RO5 Violations: 0

HBA (Lipinski): 7

HBD (Lipinski): 1

#RO5 Violations (Lipinski): 0

CX Acidic pKa:

CX Basic pKa: 1.14

CX LogP: 3.47

CX LogD: 3.47

Aromatic Rings: 3

Heavy Atoms: 26

QED Weighted: 0.62

Np Likeness Score: -1.55

References

1. Mallari JP, Shelat AA, Obrien T, Caffrey CR, Kosinski A, Connelly M, Harbut M, Greenbaum D, McKerrow JH, Guy RK..  (2008)  Development of potent purine-derived nitrile inhibitors of the trypanosomal protease TbcatB.,  51  (3): [PMID:18173229] [10.1021/jm070760l]

2. Mallari JP, Zhu F, Lemoff A, Kaiser M, Lu M, Brun R, Guy RK..  (2010)  Optimization of purine-nitrile TbcatB inhibitors for use in vivo and evaluation of efficacy in murine models.,  18  (23): [PMID:21051236] [10.1016/j.bmc.2010.09.073]

Source

Source(1):

• Scientific Literature